| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.00▼ | 1.02▼ | 1.02▼ | 0.99▲ | 1.03▼ |
| MA10 | 1.01▼ | 0.99▲ | 1.00▲ | 0.98▲ | 1.14▼ |
| MA20 | 0.99▲ | 1.00▲ | 1.00▼ | 1.04▼ | 1.23▼ |
| MA50 | 1.02▼ | 1.07▼ | 1.08▼ | 1.23▼ | 1.36▼ |
| MA100 | 1.18▼ | 1.31▼ | 1.36▼ | 1.26▼ | 1.20▼ |
| MA200 | 1.44▼ | 1.34▼ | 1.29▼ | 1.44▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | 0.010▲ | 0.010▲ | 0.009▲ | -0.038▼ |
| RSI | 49.026▼ | 45.707▼ | 44.727▼ | 42.364▼ | 43.442▼ |
| STOCH | 48.521 | 61.022 | 61.022 | 41.818 | 7.699▼ |
| WILL %R | -57.143 | -54.545 | -54.545 | -60.000 | -91.667▼ |
| CCI | 14.191 | 42.586 | 34.088 | 8.825 | -72.025 |
|
Sunday, March 22, 2026 10:00 PM
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or ...
|
|
Monday, February 09, 2026 11:10 AM
On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell Non-Hodgkin Lymphoma ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/06/26 | 1.06 | 1.06 | 0.985 | 1.00 | 33,827 |
| 29/06/26 | 0.96 | 1.03 | 0.95 | 1.03 | 20,094 |
| 26/06/26 | 0.95 | 0.995 | 0.95 | 0.9828 | 42,088 |
| 25/06/26 | 0.96 | 0.97 | 0.95 | 0.95 | 37,993 |
| 24/06/26 | 1.01 | 1.01 | 0.9593 | 0.98 | 46,882 |
| 23/06/26 | 0.93 | 1.1099 | 0.93 | 1.00 | 44,286 |
| 22/06/26 | 0.9701 | 0.9701 | 0.90 | 0.9341 | 33,263 |
| 18/06/26 | 1.03 | 1.03 | 0.95 | 0.95 | 51,500 |
| 17/06/26 | 1.01 | 1.02 | 0.9901 | 1.01 | 12,257 |
| 16/06/26 | 1.03 | 1.0341 | 0.99 | 1.00 | 39,527 |
|
|
||||
|
|
||||
|
|